Rocket Pharmaceuticals
RCKT
56 hedge funds and large institutions have $558M invested in Rocket Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 14 increasing their positions, 2 reducing their positions, and 15 closing their positions.
1,639% more capital invested
Capital invested by funds: $32.1M → $558M (+$526M)
600% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 2
270% more call options, than puts
Call options by funds: $825K | Put options by funds: $223K
147% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 15
67.52% more ownership
Funds ownership: 11.01% → 78.53% (+68%)
65% more funds holding
Funds holding: 34 → 56 (+22)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$244M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$48.4M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$28M |
| 4 |
BM
Bridger Management
New York
|
+$25.7M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$24.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.7M |
| 2 |
Jennison Associates
New York
|
-$3.57M |
| 3 |
SAM
Senzar Asset Management
New York
|
-$1.66M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.4M |
| 5 |
JP Morgan Chase
New York
|
-$147K |
RCKT Hedge Fund Activity: Q1 2018 in Review
56 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2018, worth a combined $558M — up 1,639% from $32.1M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new RCKT positions and 15 closed out — a net gain of 22 holders — while 14 added to existing stakes and 2 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $244M. The largest seller was Opaleye Management, exiting entirely with an estimated $4.7M sold.
- 56 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2018, up from 34 in Q4 2017.
- Funds reported $558M of Rocket Pharmaceuticals stock for Q1 2018, up 1,639% quarter-over-quarter.
- 37 funds opened new Rocket Pharmaceuticals positions in Q1 2018 and 15 closed out, a net change of +22 holders.
- The largest Rocket Pharmaceuticals buyer in Q1 2018 was RTW Investments, an estimated $244M added.
- The largest Rocket Pharmaceuticals seller in Q1 2018 was Opaleye Management, an estimated $4.7M sold.
Based on aggregated 13F filings for Q1 2018.